The medicine cabinet: What's in it, why, and can we change the contents?

Health Affairs

Volumn 23, Issue 1, 2004, Pages 23-33

  Croghan, Thomas W ^a   Pittman, Patricia M ^b  

^a RAND CORPORATION   (United States)

^b ACADEMYHEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BOTULINUM TOXIN A; CITALOPRAM; CYCLOOXYGENASE 2 INHIBITOR; FINASTERIDE; FLUOXETINE; KETOCONAZOLE; METICILLIN; OLANZAPINE; SILDENAFIL;

ALOPECIA; ANTIBIOTIC RESISTANCE; BIOLOGICAL WARFARE; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEPRESSION; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; ECONOMIC EVALUATION; ERECTILE DYSFUNCTION; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HUMAN; HYPERTENSION; INVESTMENT; MULTIDRUG RESISTANCE; NAIL INFECTION; ORGANIZATION; OSTEOARTHRITIS; PATENT; POLICY; PROSTATE HYPERTROPHY; REVIEW; TREATMENT OUTCOME; WRINKLE;

DECISION MAKING, ORGANIZATIONAL; DRUG INDUSTRY; DRUGS, ESSENTIAL; HEALTH PRIORITIES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; UNITED STATES;

EID: 4243148517     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.23.1.23     Document Type: Review

References (44)

1. U.E. Reinhardt, "Perspectives on the Pharmaceutical Industry," Health Affairs (Sep/Oct 2001): 136-149.
2. World Health Organization, World Health Organization Report on Infectious Diseases: Removing Obstacles to Healthy Development, 1999, www.who.int/ infectious-disease-report/pages/textonly.html (20 August 2003).
3. J. Brower and P. Chalk, The Global Threat of New and Emerging Infectious Diseases: Reconciling U.S. National Security and Public Health Policy (Santa Monica, Calif.: RAND, 2003).
4. U.S. Centers for Disease Control and Prevention, "Technical Fact Sheets," www.cdc.gov/drugresistance/factsheets/index.htm (2 June 2003); and WHO, "World Health Organization Report on Infectious Diseases 2000: Overcoming Antimicrobial Resistance," www.who.int/infectious-disease- report/2000/index. html (2 June 2003).
5. U.S. Centers for Disease Control and Prevention, "Technical Fact Sheets," www.cdc.gov/drugresistance/factsheets/index.htm (2 June 2003); and WHO, "World Health Organization Report on Infectious Diseases 2000: Overcoming Antimicrobial Resistance," www.who.int/infectious-disease- report/2000/index. html (2 June 2003).
6. Pharmaceutical Research and Manufacturers of America, "New Medicines in Development," 2002-2003, www.phrma.org/newmedicines/newmedsdb/drugs.cfm (2 June 2003).
7. Ibid.; and E. Yelin et al., "A National Study of Medical Care Expenditures for Musculoskeletal Conditions: The Impact of Health Insurance and Managed Care," Arthritis and Rheumatism 44, no. 5 (2001): 1160-1169.
8. Ibid.; and E. Yelin et al., "A National Study of Medical Care Expenditures for Musculoskeletal Conditions: The Impact of Health Insurance and Managed Care," Arthritis and Rheumatism 44, no. 5 (2001): 1160-1169.
9. PhRMA, "New Medicines in Development: Depression," www.phrma.org/newmedicines/newmedsdb/drugs.cfm?indicationcode=Depression|86 (2 June 2003).
10. M. Fava and K.G. Davidson, "Definition and Epidemiology of Treatment-Resistant Depression," Psychiatric Clinics of North America 19, no. 2 (1996): 179-200.
11. A.S. Young et al., "The Quality of Care for Depressive and Anxiety Disorders in the United States," Archives of General Psychiatry 58, no. 1 (2001): 55-61.
12. C.J.L. Murray and A.D. Lopez, The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 (Cambridge, Mass.: Harvard University Press, 1996); and PhRMA, "New Medicines in Development."
13. C.J.L. Murray and A.D. Lopez, The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 (Cambridge, Mass.: Harvard University Press, 1996); and PhRMA, "New Medicines in Development."
14. D. Healy, The Antidepressant Era (Cambridge, Mass.: Harvard University Press, 1997), 20-21.
15. N. Nichols, "Scientific Management at Merck: An Interview with CFO Judy Lewent," Harvard Business Review (Jan/Feb 1994): 88-99; and TW Croghan, "The Economics of Antibiotics: An Exploratory Study," in Measuring the Prices of Medical Treatments, ed. J.E. Triplett (Washington: Brookings Institution Press, 1999), 144-146.
16. N. Nichols, "Scientific Management at Merck: An Interview with CFO Judy Lewent," Harvard Business Review (Jan/Feb 1994): 88-99; and TW Croghan, "The Economics of Antibiotics: An Exploratory Study," in Measuring the Prices of Medical Treatments, ed. J.E. Triplett (Washington: Brookings Institution Press, 1999), 144-146.
17. See, for example, G. Blau et al., "Risk Management in the Development of New Products in Highly Regulated Industries," Computers and Chemical Engineering 24, nos. 2-7 (2000): 659-664; and S.B. Graves, J.L. Ringuest, and R.H. Case, "Formulating Optimal R&D Strategies," Research-Technology Management, 43, no. 3 (2000): 47-51.
18. See, for example, G. Blau et al., "Risk Management in the Development of New Products in Highly Regulated Industries," Computers and Chemical Engineering 24, nos. 2-7 (2000): 659-664; and S.B. Graves, J.L. Ringuest, and R.H. Case, "Formulating Optimal R&D Strategies," Research-Technology Management, 43, no. 3 (2000): 47-51.
19. Joint Economic Committee, United States Senate, "The Benefits of Medical Research and the Role of the NIH" (Washington: U.S. Congress, May 2000); and I. Cockburn and R. Henderson, "Public-Private Interaction and the Productivity of Pharmaceutical Research," NBER Working Paper no. 6018 (Cambridge, Mass.: National Bureau of Economic Research, April 1997).
20. Joint Economic Committee, United States Senate, "The Benefits of Medical Research and the Role of the NIH" (Washington: U.S. Congress, May 2000); and I. Cockburn and R. Henderson, "Public-Private Interaction and the Productivity of Pharmaceutical Research," NBER Working Paper no. 6018 (Cambridge, Mass.: National Bureau of Economic Research, April 1997).
21. Institute of Medicine, Scientific Opportunities and Public Needs: Improving Priority Setting and Public Input at the National Institutes of Health (Washington: National Academies Press, 1998).
22. A recent exception to this general rule has coincided with the discovery and feasibility of separating drug isomers. Thus, L-citalopram and R-fluoxetine have appeared as new antidepressant candidates. These products tend to appear as the older version's patent expires.
23. H.G. Grabowski and J.M. Vernon, "Returns to R&D on New Drug Introductions in the 1980s," Journal of Health Economics 13, no. 4 (1994): 383-406; and H.G. Grabowski, J. Vernon, and J.A. DiMasi, "Returns on Research and Development for 1990s New Drug Introductions," Pharmacoeconomics 20, supp. 3 (2002): 11-29.
24. H.G. Grabowski and J.M. Vernon, "Returns to R&D on New Drug Introductions in the 1980s," Journal of Health Economics 13, no. 4 (1994): 383-406; and H.G. Grabowski, J. Vernon, and J.A. DiMasi, "Returns on Research and Development for 1990s New Drug Introductions," Pharmacoeconomics 20, supp. 3 (2002): 11-29.
25. J. Hall and R. Viney, "Controlling Pharmaceutical Costs: The Australian Experience" (Paper presented at the AcademyHealth Annual Meeting, Nashville, Tennessee, 29 June 2003).
26. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski, "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics 22, no. 2 (2003): 151-185.
27. PhRMA, Pharmaceutical Industry Profile 2001 (Washington: PhRMA, 2001).
28. Merck's 1997 agreement with Biogen, in which Merck initially paid Biogen $15 million with milestone payments of up to $130 million to develop VLA-4 inhibitors, represents a typical example.
29. J.A. DiMasi, "New Drug Development in the United States from 1963 to 1999," Clinical Pharmacology and Therapeutics 69, no. 5 (2001): 286-296.
30. DiMasi et al., "The Price of Innovation."
31. Lilly Laboratory for Clinical Research, "About the Clinic," www.lillyclinic.com/about/history.htm (25 March 2003).
32. For example, in 1978 United Nations member states signed the Health for All 2000 agreement, which predicted a fundamental health transition in developing countries based on the ability to respond to infectious diseases.
33. IOM, Scientific Opportunities and Public Needs; M.J. Field and G.M. Gold, eds., Summarizing Population Health: Directions for the Development and Application of Population Metrics (Washington: National Academies Press, 1996); and C.P. Gross, G.F. Anderson, and N.R. Powe, "The Relation between Funding by the National Institutes of Health and the Burden of Disease," New England Journal of Medicine 340, no. 24 (1999): 1881-1887.
34. IOM, Scientific Opportunities and Public Needs; M.J. Field and G.M. Gold, eds., Summarizing Population Health: Directions for the Development and Application of Population Metrics (Washington: National Academies Press, 1996); and C.P. Gross, G.F. Anderson, and N.R. Powe, "The Relation between Funding by the National Institutes of Health and the Burden of Disease," New England Journal of Medicine 340, no. 24 (1999): 1881-1887.
35. IOM, Scientific Opportunities and Public Needs; M.J. Field and G.M. Gold, eds., Summarizing Population Health: Directions for the Development and Application of Population Metrics (Washington: National Academies Press, 1996); and C.P. Gross, G.F. Anderson, and N.R. Powe, "The Relation between Funding by the National Institutes of Health and the Burden of Disease," New England Journal of Medicine 340, no. 24 (1999): 1881-1887.
36. Gross et al., "The Relation between Funding."
37. Public Citizen, Rx R&D Myths: The Case against the Drug Industry's R&D Scare Card, July 2001, www.citizen.org/documents/rdmyths.pdf (9 October 2003).
38. Sales of today's top-selling drug, Lipitor, amount to more than $21 million per day. Pfizer Inc., Annual Report 2002, www.pfizer.com/are/mvestorsj-eports/annual_2002/index.html (10 November 2002).
39. B. Weisbrod, "Solving the Drug Dilemma," Washington Post, 22 August 2003.
40. T.W. Croghan et al., "Information Needs for Medication Coverage Decisions of a State Medicaid Program," Medical Care 37, no. 4 (1999): AS36-AS44; and P.C. Langley, "Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada: Structure, Application, and Manufacturer Responsibilities," Pharmacoeconomics 16, no. 3 (1999): 211-224.
41. T.W. Croghan et al., "Information Needs for Medication Coverage Decisions of a State Medicaid Program," Medical Care 37, no. 4 (1999): AS36-AS44; and P.C. Langley, "Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada: Structure, Application, and Manufacturer Responsibilities," Pharmacoeconomics 16, no. 3 (1999): 211-224.
42. Anne-Toni Rodgers, corporate affairs director, National Institute for Clinical Excellence, personal communication, 10 June 2003.
43. R.A. Rettig, Health Care in Transition: Technology Assessment in the Private Sector (Santa Monica, Calif.: RAND, 1997); and R.A. Rettig, "Publication of a Research Priorities Proposal," in The Role of Purchasers and Payers in the Clinical Research Enterprise (Washington: National Academies Press, 2002), 25.
44. R.A. Rettig, Health Care in Transition: Technology Assessment in the Private Sector (Santa Monica, Calif.: RAND, 1997); and R.A. Rettig, "Publication of a Research Priorities Proposal," in The Role of Purchasers and Payers in the Clinical Research Enterprise (Washington: National Academies Press, 2002), 25.